NW Bio Says Not Aware of Fundamental Reason for Friday's Decline in Pricr

Northwest Biotherapeutics

("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today issued the following statement addressing the recent highly unusual trading activity in the Company's stock: NW Bio is not aware of any fundamental reason for the substantial decline in the price of the Company's stock on Friday, October 16.  Indeed, NW Bio presented encouraging clinical data at scientific conferences in London and New York as recently as mid-September.  The Company's clinical data update included promising ongoing interim survival data from both the Phase I trial of DCVax-Direct in 13 diverse cancers, and the Information Arm of 51 patients who were unable to enroll in the Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM) brain cancer because of apparent early tumor recurrence.   In the DCVax-Direct trial for patients with multiple inoperable metastatic tumors who had failed standard treatments (including multiple different chemotherapy regimens), half of these patients are still alive with survival times now ranging up to 22 months, exceeding expected survival times. In the DCVax-L Information Arm, for the 25 GBM patients with apparent early tumor